Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Cycloserine/lurasidone (Primary) ; Lurasidone
- Indications Bipolar depression
- Focus Biomarker; Therapeutic Use
- Acronyms NRX-GLX
- Sponsors NeuroRX
- 17 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2018 Planned End Date changed from 31 Mar 2019 to 28 Feb 2020.
- 29 Nov 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Dec 2019.